Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 9, 2009, Pages 1005-1013

  Kharfan Dabaja, Mohamed A ^a   Mhaskar, Asmita R ^a   Djulbegovic, Benjamin ^a,b   Cutler, Corey ^c   Mohty, Mohamad ^d   Kumar, Ambuj ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic graft versus host disease; Meta analysis; Rituximab; Systematic review

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RITUXIMAB; STEROID;

CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; GASTROINTESTINAL DISEASE; HERPES ZOSTER; HUMAN; INFECTIOUS DIARRHEA; INFECTIOUS PNEUMONIA; LIVER DISEASE; LUNG DISEASE; MEDICAL RESEARCH; META ANALYSIS; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; ORAL MUCOSAL DISEASE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SEPSIS; SKIN DISEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRAL CONJUNCTIVITIS;

ANTIBODIES, MONOCLONAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOLOGIC FACTORS;

EID: 67849108291     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.04.003     Document Type: Review

References (27)

1. Karanes C., Nelson G.O., Chitphakdithai P., et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 14 (2008) 8-15
2. MacMillan M.L., Davies S.M., Nelson G.O., et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 14 (2008) 16-22
3. Stem Cell Trialists' Collaborative Group Allogeneic peripheral blood stem cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 23 (2005) 5074-5087
4. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 11 (2005) 945-956
5. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, IV: Response Criteria Working Group report. Biol Blood Marrow Transplant 12 (2006) 252-266
6. Lee S.J., Vogelsang G., and Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 9 (2003) 215-233
7. Couriel D., Hosing C., Saliba R., et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?. Biol Blood Marrow Transplant 12 (2006) 37-40
8. Foss F.M., DiVenuti G.M., Chin K., et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 35 (2005) 1187-1193
9. Kim J.G., Sohn S.K., Kim D.H., et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 73 (2004) 56-61
10. Takami A., Mochizuki K., Okumura H., et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol 83 (2006) 80-85
11. Giaccone L., Martin P., Carpenter P., et al. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant 36 (2005) 337-341
12. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 105 (2005) 2973-2978
13. Stuart A., and Ord J. Kendall's Advanced Theory of Statistics (1994), Edward Arnold, London
14. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
15. Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions, version 5.0.0 [updated February 2008]. Available from: www.cochrane-handbook.org.
16. Egger M., Smith D.G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
17. Peters J.L., Sutton A.J., Jones D.R., et al. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med 26 (2007) 4544-4562
18. von Bonin M., Oelschlagel U., Radke J., et al. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 86 (2008) 875-879
19. Canninga-van Dijk M.R., van der Straaten H.M., Fijnheer R., et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 104 (2004) 2603-2606
20. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108 (2006) 756-762
21. Mohty M., Marchetti N., El-Cheikh J., et al. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 41 (2008) 909-911
22. Okamoto M., Okano A., Akamatsu S., et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 20 (2006) 172-173
23. Ratanatharathorn V., Ayash L., Reynolds C., et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 9 (2003) 505-511
24. Zaja F., Bacigalupo A., Patriarca F., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 40 (2007) 273-277
25. Eisenberg R., and Looney R.J. The therapeutic potential of anti-CD20: "what do B-cells do?". Clin Immunol 117 (2005) 207-213
26. + malignancies and does not affect timely hematopoietic engraftment. Biol Blood Marrow Transplant 14 (2008) 121-122
27. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111 (2008) 5530-5536